ArticlePharmaceuticals (Basel, Switzerland)2025

Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study.

Klaus Francke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.